# Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer

> **NCT02595138** · PHASE3 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 430 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT02595138
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10
- **Primary completion:** 2018-10
- **Final completion:** 2023-12
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2015-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02595138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02595138, "Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02595138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*